Avenue Therapeutics' subsidiary Baergic Bio acquired by Axsome for up to $82M milestones plus royalties

AVENUE THERAPEUTICS, INC.

Axsome acquires 100% of Baergic Bio equity for $0.3M upfront; development/regulatory milestones up to $2.5M (first indication) and $1.5M per subsequent indication.
Sales-based milestones up to $79M; tiered mid-to-high single digit royalty on global net sales of AXS-17 (formerly BAER-101).
Avenue expects to receive ~74% of all future payments and royalties.
Axsome receives worldwide rights to BAER-101 (GABA A PAM) to be evaluated for epilepsy.
CEO granted 443,578 restricted shares; CFO granted 266,147 restricted shares, fully vesting upon closing.

item 1.01 item 5.02 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001437749-25-034243
form_type: 8-K
ticker: ATXI
cik: 0001644963
company_name: AVENUE THERAPEUTICS, INC.
filed_at: 2025-11-12T23:59:59+00:00
discovered_at: 2026-05-14T18:02:40.028493+00:00
generated_at: 2026-05-16T21:15:53.662701+00:00
sec_items: ["1.01", "5.02", "8.01", "9.01"]
event_type: m_and_a
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001437749-25-034243
json_url: https://secwatch.observer/filing/0001437749-25-034243.json
markdown_url: https://secwatch.observer/filing/0001437749-25-034243.md
text_url: https://secwatch.observer/filing/0001437749-25-034243.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1644963/000143774925034243/0001437749-25-034243-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1644963/000143774925034243/atxi20250430_8k.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001437749-25-034243

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.